New hope for rare cancer: oral pill targets early mesothelioma in High-Risk patients
NCT ID NCT05960773
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral medication (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma that is not yet causing symptoms. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will receive treatment and be monitored for side effects and how long the cancer stays controlled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which palliative care approach boosts quality of life in advanced lung cancer?
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Abdominal chemotherapy after surgery may improve mesothelioma outcomes
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Engineered immune cells take aim at Mesothelin-Positive tumors